Abstract: A compound of formula I: ##STR1## wherein either (i) each of R.sub.1 and R.sub.2 independently represents a hydrogen atom or an organic group, or (ii) R.sub.1 and R.sub.2 linked together form a heterocyclic ring or (iii) R.sub.2 is hydrogen and R.sub.1 is ##STR2## wherein each of R.sub.6 and R.sub.7 independently represents hydrogen or an organic group, n is 0-3, X is O, S, NH, NR.sub.8, CHNO.sub.2 or CHSO.sub.2 R.sub.4, wherein R.sub.8 and R.sub.4 are organic groups and R.sub.3 represents an organic group. The compound of formula I is effective as an anti-ulcer agent and is highly effective as a histamine H.sub.2 -receptor antagonist.

Abstract: The present invention relates to new furyl derivatives of 16-substituted prostaglandins, to a process for their preparation and to pharmaceutical and veterinary compositions containing them.The new compounds of the invention are optically active or racemic prostaglandins of the following formula (I) ##STR1## wherein R is(1) --OH or --OR' wherein R' is C.sub.1 -C.sub.6 alkyl optionally substituted by phenyl or by a monocycloalkyl group or by a pentatomic or hexatomic heteromonocyclic ring containing at least one heteroatom chosen from O, S and N;(2) ##STR2## wherein each of R" and R"', is independently, hydrogen; C.sub.1 -C.sub.6 alkyl; phenyl; or a pentatomic or hexatomic heteromonocyclic ring containing at least one heteroatom chosen from O, S and N; or R" and R"', together with the nitrogen atom to which they are linked, form a pentatomic or hexatomic heteromonocyclic ring optionally containing a further heteroatom chosen from O, S and N;(3) --W--(CH.sub.2).sub.

Abstract: Omega furyl prostenynoic acids have been prepared.

Abstract: .omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandin compounds, specifically 5c-9-oxo-11.alpha.,15S-dihydroxy-20,19,18-tirnor-17-cyclohexyl-prost-5-en- 13-ynoic acid, the esters and salts thereof, having antiulcer and luteolytic activity, are disclosed.

Abstract: 2-oxa-bicyclic prostaglandins are provided, together with methods for their preparation and pharmaceutical and veterinary compositions containing same. The compounds have a wide range of pharmacological utilities, such as hypotensive agents, vasodilatory agents, and anti-aggregating agents.

Abstract: 15-Epi-Prostacyclin derivatives and compositions containing them having numerous pharmaceutical and veterinary utilities including, for example, anti-aggregating activity and anti-thrombolytic activity. Methods for preparing and using the compounds are also disclosed.

Abstract: 9-deoxy-9A-methylene-isosteres of PGI.sub.2, including processes for their preparation and pharmaceutical and veterinary compositions containing same, are disclosed. The compounds are useful as therapeutic agents, for example as anti-aggregating agents, disaggregating agents, and as vasodilators.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Abstract: Bicyclic prostaglandins and pharamaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds are also disclosed.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, antiaggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Abstract: Bicyclic Prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

Abstract: Bicyclic prostaglandins having numerous pharmaceutical and veterinary utilities including, for example, use as hypotensive, vasodilatory, anti-aggregating, cytoprotective, and bronchodilatory agents. Pharmaceutical and veterinary compositions comprising the compounds in combination with pharmaceutically and/or veterinarily acceptable carriers and/or diluents are also disclosed.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them, having numerous pharmaceutical and veterinary utilities, including for example hypotensive, vasodilatory, anti-aggregating, and anti-thrombotic activities. Methods for preparing the compounds and compositions are also disclosed.

Abstract: 2-Oxa-bicyclic prostaglandins, a method for their preparation and pharmaceutical and veterinary compositions containing them are disclosed.

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, antiaggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Abstract: New 2-oxa-bicyclic prostaglandin compounds, and pharmaceutical and veterinary compositions containing them, having pharmaceutical utility for example as anti-aggregating, vasodilating, and cytoprotective agents. Processes for preparing the compounds are also disclosed.

Abstract: PGF.sub..alpha. compounds are disclosed having as the lower side chain ##STR1## in which one of R.sub.4 and R.sub.5 hydroxyl and the other is alkoxy R.sub.6 is hydrogen or alkyl, m is 0-3, E represents oxygen or sulphur and R is hydrogen, halogen, alkyl, alkoxy or trihaloalkyl.

Abstract: .omega.-NOR-CYCLOALKYL-13,14-DEHYDRO-PROSTAGLANDIN COMPOUNDS, SPECIFICALLY 13,14-DEHYDRO-17-CYCLOHEXYL-20,19,18-TRINOR-PGF.sub.2.alpha. having antiulcer and luteolytic activity, are disclosed.